Drug intelligence / Profile preview

AiYu capsule

Development stage: Unknown
Lead developer: Guizhou Yibai Pharmaceutical
Administration: Oral

Overview

AiYu capsule is a traditional Chinese medicine undergoing clinical investigation for its efficacy and safety in various cancer-related conditions. It has been studied in combination with chemotherapy for malignant lymphoma and non-small cell lung cancer. Additionally, it is being evaluated for the treatment of chemotherapy-related myelosuppression, specifically leukopenia, in patients with gastric cancer, colorectal cancer, ovarian cancer, and lymphoma.

Other names: AiYu艾愈艾愈胶囊

Beyond the preview

Go deeper on AiYu capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AiYu capsule.

Explore the full profile